Vaccine Therapy In Recurrent Herpes Simplex

Kern, Arthur B.; Schiff, Bencel L.

doi:10.1001/archderm.1964.01590300072021

Cited by 53 publications

(16 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the main these are uncontrolled trials [e.g., Dundarov et al, 1982;Skinner et al, 1982], Where double-blind trials have been carried out the results have been less than satisfactory [e.g., Kern and Schiff, 1964;Hilleman et al, 1982], It is quite possible that these inert antigens are too feeble as immunogens, though from our earlier considerations it may be that too much is being asked of a faulty immune sys tem. If the former is true, we should expect quite powerful vaccines to be made now that glycoproteins can be genetically engineered relatively easily [e.g., Berman et al, 1985].…”

Section: Controlmentioning

confidence: 99%

Herpesvirus

Wildy¹

1986

Intervirology

View full text Add to dashboard Cite

Section: Controlmentioning

confidence: 99%

Herpesvirus

Wildy¹

1986

Intervirology

View full text Add to dashboard Cite

“…From the 1940s to the 1960s, vaccine virus was grown in embryonated eggs and later in cell cultures, and inactivated by UV irradiation, heat or chemicals. The first randomized, double-blind, placebo-controlled clinical trial of an HSV vaccine was conducted by Kern and Schiff in 1964 [46]. Formaldehyde-inactivated whole virus vaccine was administered to patients with recurrent HSV.…”

Section: History Of Hsv-2 Vaccines Tested In Clinical Studiesmentioning

confidence: 99%

The challenge of developing a herpes simplex virus 2 vaccine

Dropulic¹,

Cohen

2012

Expert Review of Vaccines

View full text Add to dashboard Cite

HSV infections are prevalent worldwide. A vaccine to prevent genital herpes would have a significant impact on this disease. Several vaccines have shown promise in animal models; however, so far these have not been successful in human clinical studies. Prophylactic HSV vaccines to prevent HSV infection or disease have focused primarily on eliciting antibody responses. Potent antibody responses are needed to result in sufficiently high levels of virus-specific antibody in the genital tract. Therapeutic vaccines that reduce recurrences need to induce potent T-cell responses at the site of infection. With the increasing incidence of HSV-1 genital herpes, an effective herpes vaccine should protect against both HSV-1 and HSV-2. Novel HSV vaccines, such as replication-defective or attenuated viruses, have elicited humoral and cellular immune responses in preclinical studies. These vaccines and others hold promise in future clinical studies.

show abstract

“…Inactivated whole virus vaccines prolong the inter‐recurrence interval of HSV‐2 infection with studies reporting clinical improvement in 65–80% of patients 89,90 . In a placebo‐controlled clinical trial, 70% of patients with HSV‐2 had fewer recurrences and 76% had less severe recurrences 91 …”

Section: Genital Herpes Simplex Virusmentioning

confidence: 99%

Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options

et al. 2010

View full text Add to dashboard Cite

Human papillomavirus and Herpes simplex virus are the most common genital viral infections encountered in clinical practice worldwide. We reviewed the literature focusing on new and experimental treatment modalities for both conditions, based on to the evidence-based data available. The modalities evaluated include topical agents such as immune response modifiers (imiquimod, resiquimod, and interferon), antivirals (penciclovir, cidofovir, and foscarnet), sinecatechins, microbiocidals (SPL7013 gel, and PRO 2000 gel), along with experimental (oligodeoxynucleotides), immunoprophylactic, and immunotherapeutic vaccines.

show abstract

Vaccine Therapy In Recurrent Herpes Simplex

Cited by 53 publications

References 2 publications

Herpesvirus

Herpesvirus

The challenge of developing a herpes simplex virus 2 vaccine

Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options

Contact Info

Product

Resources

About